Nicotine DependencePhase 1Extinction01NCT00831155
Extinction Based Treatment for Nicotine Dependence
A Phase 1 study testing Nicotine Patches, Denicotinized Cigarettes in people with Nicotine Dependence, run by Duke University at 1 site in United States.
Trial summary
The purpose of this study is to test two quit smoking therapies and to study brain function while each therapy is being used. You will be randomly assigned (like flipping a coin) to one of the two groups. The first therapy is Extinction-Based therapy (EBT). Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Nicotine Dependence
- What is being tested?
- Nicotine Patches, Denicotinized Cigarettes
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 257 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2009to Dec 2014
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- generally healthy,
- between the ages of 18 and 55,
- smoking of at least 10 cigarettes/day of a brand delivering >0.5mg nicotine according to the standard Federal Trade Commission (FTC) method,
- an afternoon expired CO concentration of at least 10 ppm (to confirm inhalation),
- an interest in quitting smoking
- right-handed
Show all 15Show fewer
- generally healthy,
- between the ages of 18 and 55,
- prior history of smoking of at least 10 conventional cigarettes/day for at least two years of a brand delivering >0.5mg nicotine according to the standard Federal Trade Commission (FTC) method,
- no smoking of conventional cigarettes in the last 6 months;
- daily use of a nicotine-containing e-cigarette for at least 3 months;
- taking of at least 100 puffs per day from a nicotine-containing e-cigarette;
- an afternoon expired CO concentration <5 ppm (to confirm they are not combustible cigarette users);
- nicotine test strip reading >3
- right-handed
Who cannot join
- inability to attend all required experimental sessions,
- significant health problems (e.g., chronic hypertension (BP>150/90 sitting after 10 minutes), emphysema, seizure disorder, history of significant heart problems),
- use of psychoactive medications,
- use of smokeless tobacco,
- liver or kidney disorder (except kidney stones, gallstones)
- lung disorder (including but not limited to COPD, emphysema, and asthma)
Show all 12Show fewer
- report of coronary heart disease; heart attack; cardiac rhythm disorder (irregular heart rhythm; chest pains; cardiac disorder (including but not limited to valvular heart disease, heart murmur, heart failure)
- current alcohol or drug abuse,
- use of illegal drugs as measured by urine drug screen,
- current use of nicotine replacement therapy or other smoking cessation treatment,
- presence of conditions that would make MRI unsafe (e.g., pacemaker, metal objects in the body, IUD, orthopedic pins or screws, etc.), or
- presence of conditions contraindicated for nicotine replacement therapy (e.g., skin allergies or disorders).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Brain Substrates of Extinction Based Treatment for Nicotine Dependence
The purpose of this study is to test two quit smoking therapies and to study brain function while each therapy is being used. You will be randomly assigned (like flipping a coin) to one of the two groups. The first therapy is Extinction-Based therapy (EBT). If you are in this group, you will switch to smoking denicotinized cigarettes while wearing a 21 mg/d nicotine patch for one month prior to your quit date. The second therapy is a standard Nicotine Replacement therapy (NRT). If you are in this group, you will smoke your usual brand of cigarettes up to the quit date. Following the quit date, both groups will undergo standard nicotine replacement therapy (21 mg/d for 6 weeks; 14 mg/d for 2 weeks, 7 mg/d for 2 weeks).
In addition to the above, we will recruit a sample of former smokers who are now regular users of e-cigarettes. This group [ECIG] will undergo the same screening and baseline assessments as the EBT and NRT groups up to the completion of fMRI1.
Read the detailed description
If you agree to be in this study, you will be asked to sign the consent form prior to any tests or procedures. You will be asked to come to the laboratory for a screening session. The screening session will take approximately 1.5 hours to complete, including all questionnaires, physical and sample collection. Pregnant or nursing mothers will not be allowed to participate in this study. If you test positive for illegal drug use, you will not be allowed to participate in this study. Depending on the results of the screening procedures you may not be eligible for the study. If you do not have any medical conditions that would make your participation risky, and you feel comfortable participating in the study, you will be given instructions regarding the rest of the study sessions and be asked to return.
Smoker participants who complete the screening visit (described above) and meet all study requirements will then complete 8 lab visits, 1 fMRI training session, 3 fMRI sessions, and 2 follow-up visits. ECIG participants who complete the screening visit and meet all study requirements will complete 1 fMRI training session and 1 fMRI session.
First you will be randomly assigned (like drawing out of a hat) to a study group, either the EBT or NRT group. In the extinction-based therapy (EBT) group, participants will switch to smoking denicotinized cigarettes while wearing a 21 mg/d nicotine patch for one month prior to their quit date; meanwhile, smokers assigned to the nicotine replacement therapy (NRT) group will smoke their usual brand of cigarettes up to the quit date. Following the quit date, both groups will undergo standard nicotine replacement therapy (21 mg/d for 6 weeks; 14 mg/d for 2 weeks, 7 mg/d for 2 weeks).
Eight lab visits (V1 - V8) will be conducted during the 16 weeks following enrollment in the study. These visits will be largely identical, except that instructions and reminders to you about upcoming events will vary from session to session. At each lab visit the following will be collected: vitals (heart rate, blood pressure and weight); breath CO (Carbon Monoxide) and saliva samples for testing smoking and nicotine levels; and measures of smoking withdrawal and mood. You will be given daily diaries to record your smoking behavior and study medication. You will be given instructions on how and when to use all study materials. Advice on quitting and minimal support will be provided as requested at these visits. Each lab visit will require 20-30 minutes of your time.
Directly following V1 you will undergo a training session, during which you will be familiarized with all aspects of the fMRI sessions including tasks and equipment. You will be situated in a scanner simulator, which simulates the sounds and equipment used in the fMRI scanner.
One task will require you to view pictures of people smoking and people doing everyday activities. After the task, you will be quizzed on the pictures you saw. During another task, you will be presented with a stream of gray, yellow, or blue colored circles and instructed to press a button every time you see a "Go" trial while inhibiting a response (not pressing the button) when you are presented with a "No-Go" trial. The training session will require 1 hour of participant time.
fMRI Sessions:
You will be asked to complete three fMRI scanning sessions: a baseline scan (fMRI-1); a scan 4 weeks after you start treatment (fMRI-2); and a final scan 24 hours after your quit date (fMRI-3). The first 20 minutes of each scanning session will follow the same protocol as a lab visit. Following this, for fMRI-1 and fMRI-2 you will be asked to smoke a cigarette (usual brand or denicotinized depending on session and group). No cigarette will be smoked prior to fMRI-3. After smoking your cigarette you will sit in a quiet room and read magazines for 30 minutes. Following the 30 min rest period, you will be escorted to the fMRI suite at Duke University Medical Center. Once inside, you will complete questionnaires regarding your current mood and withdrawal symptoms. We will take a CO and saliva sample at the beginning of each scan. If you are wearing a nicotine replacement patch, you will remove it before entering the scanner. Then you will be given specific instructions regarding data collection procedures and be placed in the scanner. During the scanning you will perform each of the tasks, and lie still while we take pictures of your brain. After being removed from the scanner, you will complete post-session withdrawal and mood questionnaires and replace the removed patch. End-of-session instructions will then be provided:
- At the end of fMRI-1, ECIG participants will be released from the study. Smoker participants will be randomly assigned to either the EBT or NRT group, and given supplies and information regarding upcoming sessions.
- At the end of fMRI-2, you will be reminded of the quit date which you agreed upon previously, and you will be given supplies and information regarding quitting.
- At the end of fMRI-3, you will be given reminders about upcoming sessions.
You will be instructed not to consume any alcohol on the night before each scanning session.
We will ask for a breath and saliva sample before each session to make sure you have followed all directions about wearing the patch and smoking your usual brand or the denicotinized cigarettes as instructed. If the test indicates that you have not followed directions, you will be sent home (this will be considered a missed visit) and the visit will be re-scheduled. If this occurs on 2 consecutive visits, your further participation in the study will be terminated.
Follow-Up Sessions:
After completing all study visits, you will be asked to return for two follow-up sessions, one at 6 months and one at 12 months from visit 1. At these follow-up sessions we will ask for breath and saliva samples, and have you fill out paperwork regarding your mood and current smoking status.
- Conditions
- Nicotine Dependence
- Being tested
- Nicotine Patches, Denicotinized Cigarettes
- Keywords
- smoking, nicotine patches, extinction based treatment
- Medical subject headings
- Tobacco Use Disorder, Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nicotine Patches, Denicotinized CigarettesDrug
Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | Extinction Based Group (EBT): switch to smoking denicotinized cigarettes while wearing a 21mg/day nicotine patch for one month prior to their quit date. Receives: Drug: Nicotine Patches, Denicotinized Cigarettes |
| 2 | No intervention | Nicotine Replacement Group (NRT): smoke their usual brand of cigarettes up to the quit date. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To test two quit smoking therapies and to study brain function while each therapy is being used.
Measured: 14 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2009 (estimated)
- Study startJan 2009
- Primary completionDec 2014
- Study completionDec 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nicotine DependenceStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 257 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Francis J McClernon, Ph.D, Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00831155
- Sponsor's protocol ID
- Pro00009639
- Acronym
- Extinction01
- Status last verified
- Apr 2015
- First submitted
- 27 Jan 2009
- Last updated
- 20 Apr 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Brain Substrates of Extinction Based Treatment for Nicotine Dependence
- ClinicalTrials.gov ID
- NCT00831155
- Acronym / sponsor ID
- Extinction01 / Pro00009639
- Conditions
- Nicotine Dependence
- Keywords
- smoking, nicotine patches, extinction based treatment
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 257 participants (actual)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Study start
- Jan 2009
- Primary completion
- Dec 2014 (actual)
- Study completion
- Dec 2014 (actual)
- First posted
- 28 Jan 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test two quit smoking therapies and to study brain function while each therapy is being used. You will be randomly assigned (like flipping a coin) to one of the two groups. The first therapy is Extinction-Based therapy (EBT). If you are in this group, you will switch to smoking denicotinized cigarettes while wearing a 21 mg/d nicotine patch for one month prior to your quit date. The second therapy is a standard Nicotine Replacement therapy (NRT). If you are in this group, you will smoke your usual brand of cigarettes up to the quit date. Following the quit date, both groups will undergo standard nicotine replacement therapy (21 mg/d for 6 weeks; 14 mg/d for 2 weeks, 7 mg/d for 2 weeks).
In addition to the above, we will recruit a sample of former smokers who are now regular users of e-cigarettes. This group [ECIG] will undergo the same screening and baseline assessments as the EBT and NRT groups up to the completion of fMRI1.
Detailed description
If you agree to be in this study, you will be asked to sign the consent form prior to any tests or procedures. You will be asked to come to the laboratory for a screening session. The screening session will take approximately 1.5 hours to complete, including all questionnaires, physical and sample collection. Pregnant or nursing mothers will not be allowed to participate in this study. If you test positive for illegal drug use, you will not be allowed to participate in this study. Depending on the results of the screening procedures you may not be eligible for the study. If you do not have any medical conditions that would make your participation risky, and you feel comfortable participating in the study, you will be given instructions regarding the rest of the study sessions and be asked to return.
Smoker participants who complete the screening visit (described above) and meet all study requirements will then complete 8 lab visits, 1 fMRI training session, 3 fMRI sessions, and 2 follow-up visits. ECIG participants who complete the screening visit and meet all study requirements will complete 1 fMRI training session and 1 fMRI session.
First you will be randomly assigned (like drawing out of a hat) to a study group, either the EBT or NRT group. In the extinction-based therapy (EBT) group, participants will switch to smoking denicotinized cigarettes while wearing a 21 mg/d nicotine patch for one month prior to their quit date; meanwhile, smokers assigned to the nicotine replacement therapy (NRT) group will smoke their usual brand of cigarettes up to the quit date. Following the quit date, both groups will undergo standard nicotine replacement therapy (21 mg/d for 6 weeks; 14 mg/d for 2 weeks, 7 mg/d for 2 weeks).
Eight lab visits (V1 - V8) will be conducted during the 16 weeks following enrollment in the study. These visits will be largely identical, except that instructions and reminders to you about upcoming events will vary from session to session. At each lab visit the following will be collected: vitals (heart rate, blood pressure and weight); breath CO (Carbon Monoxide) and saliva samples for testing smoking and nicotine levels; and measures of smoking withdrawal and mood. You will be given daily diaries to record your smoking behavior and study medication. You will be given instructions on how and when to use all study materials. Advice on quitting and minimal support will be provided as requested at these visits. Each lab visit will require 20-30 minutes of your time.
Directly following V1 you will undergo a training session, during which you will be familiarized with all aspects of the fMRI sessions including tasks and equipment. You will be situated in a scanner simulator, which simulates the sounds and equipment used in the fMRI scanner.
One task will require you to view pictures of people smoking and people doing everyday activities. After the task, you will be quizzed on the pictures you saw. During another task, you will be presented with a stream of gray, yellow, or blue colored circles and instructed to press a button every time you see a "Go" trial while inhibiting a response (not pressing the button) when you are presented with a "No-Go" trial. The training session will require 1 hour of participant time.
fMRI Sessions:
You will be asked to complete three fMRI scanning sessions: a baseline scan (fMRI-1); a scan 4 weeks after you start treatment (fMRI-2); and a final scan 24 hours after your quit date (fMRI-3). The first 20 minutes of each scanning session will follow the same protocol as a lab visit. Following this, for fMRI-1 and fMRI-2 you will be asked to smoke a cigarette (usual brand or denicotinized depending on session and group). No cigarette will be smoked prior to fMRI-3. After smoking your cigarette you will sit in a quiet room and read magazines for 30 minutes. Following the 30 min rest period, you will be escorted to the fMRI suite at Duke University Medical Center. Once inside, you will complete questionnaires regarding your current mood and withdrawal symptoms. We will take a CO and saliva sample at the beginning of each scan. If you are wearing a nicotine replacement patch, you will remove it before entering the scanner. Then you will be given specific instructions regarding data collection procedures and be placed in the scanner. During the scanning you will perform each of the tasks, and lie still while we take pictures of your brain. After being removed from the scanner, you will complete post-session withdrawal and mood questionnaires and replace the removed patch. End-of-session instructions will then be provided:
- At the end of fMRI-1, ECIG participants will be released from the study. Smoker participants will be randomly assigned to either the EBT or NRT group, and given supplies and information regarding upcoming sessions.
- At the end of fMRI-2, you will be reminded of the quit date which you agreed upon previously, and you will be given supplies and information regarding quitting.
- At the end of fMRI-3, you will be given reminders about upcoming sessions.
You will be instructed not to consume any alcohol on the night before each scanning session.
We will ask for a breath and saliva sample before each session to make sure you have followed all directions about wearing the patch and smoking your usual brand or the denicotinized cigarettes as instructed. If the test indicates that you have not followed directions, you will be sent home (this will be considered a missed visit) and the visit will be re-scheduled. If this occurs on 2 consecutive visits, your further participation in the study will be terminated.
Follow-Up Sessions:
After completing all study visits, you will be asked to return for two follow-up sessions, one at 6 months and one at 12 months from visit 1. At these follow-up sessions we will ask for breath and saliva samples, and have you fill out paperwork regarding your mood and current smoking status.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Drug: Nicotine Patches, Denicotinized CigarettesExtinction Based Group (EBT): switch to smoking denicotinized cigarettes while wearing a 21mg/day nicotine patch for one month prior to their quit date. |
| 2 | No intervention | –Nicotine Replacement Group (NRT): smoke their usual brand of cigarettes up to the quit date. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (15 listed)
- generally healthy,
- between the ages of 18 and 55,
- smoking of at least 10 cigarettes/day of a brand delivering >0.5mg nicotine according to the standard Federal Trade Commission (FTC) method,
- an afternoon expired CO concentration of at least 10 ppm (to confirm inhalation),
- an interest in quitting smoking
Key exclusion criteria (12 listed)
- inability to attend all required experimental sessions,
- significant health problems (e.g., chronic hypertension (BP>150/90 sitting after 10 minutes), emphysema, seizure disorder, history of significant heart problems),
- use of psychoactive medications,
- use of smokeless tobacco,
- liver or kidney disorder (except kidney stones, gallstones)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nicotine Patches, Denicotinized CigarettesBoth groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date | Drug | 1 |
Primary outcome
To test two quit smoking therapies and to study brain function while each therapy is being used.
Time frame: 14 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2015.
Related trials for Nicotine Dependence
Recruiting
Use of Nicotine Pouches Among Daily Smokers
Tobacco Dependence
Recruiting
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
Drug Abuse, Nicotine Dependence
Not yet recruiting
Quit With Sense: Using Mindful Smoking and Wearable Device for Smoking Cessation
Smoking Cessation, Cigarette Smoking
Recruiting
Adapting and Pilot Testing a Skills-based Smoking Cessation Intervention to Address Developmental and Health-related Stress Among Adults Who Smoke
Smoking Cessation, Depression
Not yet recruitingPhase 2
Effects of Psilocybin on Craving in Nicotine Dependence
Nicotine Dependence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Francis J McClernon, Ph.D principal investigator
Duke University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Nicotine Patches, Denicotinized Cigarettes in people with Nicotine Dependence, run by Duke University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To test two quit smoking therapies and to study brain function while each therapy is being used. (time frame: 14 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2015.